Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Wei Jing

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4170-7259; OpenAlex author ID A5100621122. Sources: OpenAlex.

Their work

Papers
10
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 10

  1. Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors. Co-author DOI 10.34133/bmr.0335↗
  2. Pathogenic germline variants in Chinese pancreatic adenocarcinoma patients. Co-author DOI 10.1038/s41467-025-57520-3↗
  3. The Landscape of Genetic Alterations Stratified Prognosis in Oriental Pancreatic Cancer Patients. Co-author DOI 10.3389/fonc.2021.717989↗
  4. PD-L1 upregulation accompanied with epithelial-mesenchymal transition attenuates sensitivity to ATR inhibition in p53 mutant pancreatic cancer cells. Co-author DOI 10.1007/s12032-020-01372-y↗
  5. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. Co-author DOI 10.21037/cco-20-6↗
  6. DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer. Co-author DOI 10.2147/cmar.s201610↗
  7. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. Co-author DOI 10.2147/ott.s181792↗
  8. DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells. Co-author DOI 10.3892/mmr.2017.7923↗
  9. Serum calcium level used as a prognostic predictor in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.clinre.2014.01.012↗
  10. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.1186/1477-7819-12-171↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gang Li · 3 shared papers, 2020–2025 · strength 0.35
  2. Shiwei Guo · 3 shared papers, 2020–2025 · strength 0.35
  3. Gang Jin · 3 shared papers, 2020–2025 · strength 0.35
  4. Wei Li · 1 shared paper, 2026 · strength 0.30
  5. Di Chen · 1 shared paper, 2026 · strength 0.30
  6. Huojun Zhang · 1 shared paper, 2026 · strength 0.30
  7. Na Song · 3 shared papers, 2018–2020 · strength 0.30
  8. Xiaofang Che · 3 shared papers, 2018–2020 · strength 0.30
  9. Suizhi Gao · 2 shared papers, 2021–2025 · strength 0.26
  10. Kailian Zheng · 2 shared papers, 2021–2025 · strength 0.26
  11. Xiongfei Xu · 2 shared papers, 2021–2025 · strength 0.26
  12. Guoxiao Zhang · 2 shared papers, 2021–2025 · strength 0.26
  13. Xiaohan Shi · 2 shared papers, 2021–2025 · strength 0.26
  14. Ce Li · 2 shared papers, 2019–2020 · strength 0.21
  15. Xiujuan Qu · 3 shared papers, 2014–2018 · strength 0.18
  16. Chunming Zhang · 1 shared paper, 2025 · strength 0.16
  17. Yunguang Li · 1 shared paper, 2025 · strength 0.16
  18. Bin Song · 1 shared paper, 2025 · strength 0.16
  19. Xiaoyi Yin · 1 shared paper, 2025 · strength 0.16
  20. Meilong Shi · 1 shared paper, 2025 · strength 0.16
  21. Dong Gao · 1 shared paper, 2025 · strength 0.16
  22. Yunpeng Liu · 1 shared paper, 2020 · strength 0.11
  23. Bo Li · 1 shared paper, 2021 · strength 0.10
  24. Shuo Shen · 1 shared paper, 2021 · strength 0.10
  25. Jing Shen · 1 shared paper, 2021 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.